ASND vs. REGN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ASND and REGN, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
REGN stands out with 64.18 billion USD in market value—about 6.72× ASND’s market cap of 9.55 billion USD.
With betas of 0.40 for ASND and 0.43 for REGN, both show similar volatility profiles relative to the overall market.
ASND trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while REGN remains a standard domestic listing.
Symbol | ASND | REGN |
---|---|---|
Company Name | Ascendis Pharma A/S | Regeneron Pharmaceuticals, Inc. |
Country | DK | US |
Sector | Healthcare | Healthcare |
Industry | Biotechnology | Biotechnology |
CEO | Mr. Jan Moller Mikkelsen | Dr. Leonard S. Schleifer M.D., Ph.D. |
Price | 158.1 USD | 604.62 USD |
Market Cap | 9.55 billion USD | 64.18 billion USD |
Beta | 0.40 | 0.43 |
Exchange | NASDAQ | NASDAQ |
IPO Date | January 28, 2015 | April 2, 1991 |
ADR | Yes | No |
Performance Comparison
This chart compares the performance of ASND and REGN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ASND and REGN based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ASND posts a negative P/E of -24.55, reflecting last year’s net loss, while REGN at 14.34 signals healthy earnings.
- ASND posts a negative forward PEG of -2.23, hinting at anticipated earnings decline, whereas REGN at 1.09 has projections for stable or growing earnings.
- ASND has a negative P/B ratio of -44.20, indicating its liabilities exceed assets (negative equity). REGN, with a P/B of 2.20, maintains positive shareholder equity.
- ASND has a negative Price-to-Free Cash Flow ratio of -27.43, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, REGN (P/FCF 21.25) indicates positive free cash flow generation.
Symbol | ASND | REGN |
---|---|---|
Price-to-Earnings Ratio (P/E, TTM) | -24.55 | 14.34 |
Forward PEG Ratio (TTM) | -2.23 | 1.09 |
Price-to-Sales Ratio (P/S, TTM) | 22.89 | 4.56 |
Price-to-Book Ratio (P/B, TTM) | -44.20 | 2.20 |
Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -27.43 | 21.25 |
EV-to-EBITDA (TTM) | -35.74 | 12.81 |
EV-to-Sales (TTM) | 23.78 | 4.53 |
EV-to-Free Cash Flow (TTM) | -28.50 | 21.12 |
Dividend Comparison
ASND offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while REGN provides a 0.29% dividend yield, giving investors a steady income stream.
Symbol | ASND | REGN |
---|---|---|
Dividend Yield (TTM) | 0.00% | 0.29% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ASND and REGN, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ASND’s quick ratio of 0.71 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas REGN at 4.03 maintains a comfortable buffer of liquid assets.
- ASND has negative equity (debt-to-equity ratio -4.46), an unusual warning sign, while REGN at 0.09 maintains a conventional debt-to-equity balance.
- With negative EBIT (-3.72), ASND cannot cover its interest payments. REGN, with an interest coverage of 98.59, meets its interest obligations.
Symbol | ASND | REGN |
---|---|---|
Current Ratio (TTM) | 1.04 | 4.93 |
Quick Ratio (TTM) | 0.71 | 4.03 |
Debt-to-Equity Ratio (TTM) | -4.46 | 0.09 |
Debt-to-Assets Ratio (TTM) | 0.80 | 0.07 |
Interest Coverage Ratio (TTM) | -3.72 | 98.59 |